Aegerion Pharmaceuticals Coverage Initiated at FBR & Co. (AEGR)
FBR & Co. assumed coverage on shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) in a research note issued on Wednesday, AR Network reports. The firm set an “outperform” rating on the stock.
AEGR has been the subject of a number of other recent research reports. Analysts at FBR Capital Markets initiated coverage on shares of Aegerion Pharmaceuticals in a research note to investors on Wednesday. They set an “outperform” rating and a $105.00 price target on the stock. Analysts at Lazard Capital Markets raised their price target on shares of Aegerion Pharmaceuticals from $86.00 to $105.00 in a research note to investors on Thursday, August 1st. They now have a “buy” rating on the stock. Eleven research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $89.46.
Aegerion Pharmaceuticals (NASDAQ:AEGR) traded down 2.16% during mid-day trading on Wednesday, hitting $91.30. The stock had a trading volume of 787,349 shares. Aegerion Pharmaceuticals has a 52 week low of $13.33 and a 52 week high of $97.46. The stock has a 50-day moving average of $89.65 and a 200-day moving average of $62.24. The company’s market cap is $2.645 billion.
Aegerion Pharmaceuticals (NASDAQ:AEGR) last released its earnings data on Tuesday, October 29th. The company reported ($0.43) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.50) by $0.07. The company had revenue of $16.30 million for the quarter, compared to the consensus estimate of $13.07 million. Aegerion Pharmaceuticals’s revenue was up 1629900.0% compared to the same quarter last year. Analysts expect that Aegerion Pharmaceuticals will post $-2.19 EPS for the current fiscal year.
Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.